Clinical trials for treatment of NODAT: Time to collaborate

Transplantation

Volumn 94, Issue 4, 2012, Pages

  Sharif, Adnan ^a   De Vries, Aiko P J ^b   Porrini, Esteban ^c   Hecking, Manfred ^d   Saemann, Marcus ^d  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; LIFESTYLE MODIFICATION; NEW ONSET DIABETES AFTER TRANSPLANTATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TRANSPLANTATION;

EID: 84865642085     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318260b1e9     Document Type: Letter

References (10)

1. Sarno G, Muscogiuri G, De Rosa P. New-onset diabetes after kidney transplantation: prevalence, risk factors, and management. Transplantation 2012; 93: 1189.
2. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglyce-mia. Transplantation 2008; 85: 353.
3. Turk T, Pietruck F, Dolff S, et al. Repagli-nide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6: 842.
4. Lane JT, Odegaard DE, Haire CE, et al. Sita-gliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92: e56.
5. Pietruck F, Kribben A, Van TN, et al. Rosi-glitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005; 18: 483.
6. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidine-diones and metformin in renal transplant recipients. Endocr Pract 2008; 14: 979.
7. Sharif A. Should metformin be our anti-glycemic agent of choice post-transplantation? Am J Transplant 2011; 11: 1376.
8. Larsen J. Potential risks of metformin in transplant patients. Am J Transplant 2012; 12: 795.
9. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739.
10. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panelmeeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75(10 suppl): SS3.